Newsroom
Sorted by: Latest
-
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 2026
GENEVA--(BUSINESS WIRE)--OM Pharma Unveils the Largest Multi-Country Real-World Evidence Study on Broncho Vaxom® (OM 85) for RTI Prevention at EAACI 2026...
-
NNOX Investors Have Opportunity to Lead Nano-X Imaging Ltd. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)--NNOX Investors Have Opportunity to Lead Nano-X Imaging Ltd. Securities Fraud Lawsuit with the Schall Law Firm...
-
MSFT Investors Have Opportunity to Lead Microsoft Corporation Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)--MSFT Investors Have Opportunity to Lead Microsoft Corporation Securities Fraud Lawsuit with the Schall Law Firm...
-
Gay Qatari Refugee Returns to Face Qatar at the World Cup, Standing With Senator Scott Wiener to Say Love Is Not a Crime
SAN FRANCISCO--(BUSINESS WIRE)--Today, as Qatar was welcomed back onto the world stage for its World Cup match against Switzerland, Dr. Nasser Mohamed walked in to face it. He is the first openly gay Qatari to seek asylum after fleeing state persecution, and he returned to stand a few feet from the team of the country he fled. He wore a custom bisht and stood with California State Senator Scott Wiener to make one statement clear. Love is not a crime. Dr. Nas and Senator Wiener issued the follow...
-
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced new data from two studies evaluating epcoritamab, a T-cell engaging antibody administered subcutaneously, in the first-line (1L) treatment of patients with diffuse large B-cell lymphoma (DLBCL) who may have limited treatment options due to advanced age or multiple health conditions. Results from the Phase 2 EPCORE® DLBCL-3 study showed an overall response rate (ORR) of 67% and a complete response (CR) rate of 58% wi...
-
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia
WILMINGTON, Del.--(BUSINESS WIRE)--New Positive Data Showed INCA033989 Achieved Rapid, Robust & Sustained Clinical & Molecular Responses and Was Well Tolerated in Patients with MF & ET...
-
Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif® in the United States....
-
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival
WILMINGTON, Del.--(BUSINESS WIRE)--Results from Incyte’s frontMIND Trial of Tafasitamab (Monjuvi/Minjuvi) Combination at the 2026 EHA Plenary Showed Prolonged Progression Free Survival...
-
ComEd Continues Power Restoration Following Two Powerful Storms
CHICAGO--(BUSINESS WIRE)--ComEd crews continue restoring power to customers impacted by multiple rounds of severe storms that moved through northern Illinois beginning Wednesday afternoon. With the most volatile weather now past the region, crews are focused on completing repairs and restoring service to remaining pockets of customers affected by storm damage. Multiple bands of severe weather brought intense rain, frequent lightning and high wind gusts, causing significant damage to ComEd’s pow...
-
Republic Technologies Inc. Provides Bi-Weekly Update On Annual Filings
VANCOUVER, British Columbia--(BUSINESS WIRE)--Republic Technologies Inc. (CSE: DOCT) (FSE: 7FM0) (OTCQB: DOCKF) (“Republic” or the "Company") today provided an update with respect to its previously announced management cease trade order ("MCTO") in connection with the Company's filing of its audited annual financial statements (the " Financial Statements") and management discussion and analysis (the "MD&A") for the financial year ended December 31, 2025, and the applicable CEO and CFO certi...